The humanized anti-CD147 antibody, meplazumab, could inhibit the accumulation of fibroblasts and production of ECM proteins, thus alleviating the progression of pulmonary fibrosis caused by SARS-CoV-2. The gene discussed is BSG; the disease is pulmonary fibrosis.